Evidence map›Paper›PMID 25816162›Full record

ArticlePloS one2015

Mismatch repair-deficient crypt foci in Lynch syndrome--molecular alterations and association with clinical parameters.

Laura Staffa, Fabian Echterdiek, Nina Nelius, Axel Benner, Wiebke Werft, Bernd Lahrmann, Niels Grabe, Martin Schneider, Mirjam Tariverdian, Magnus von Knebel Doeberitz and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Therapeutic targeting of mismatch repair-deficient cancers.Nature reviews. Clinical oncology · 2025
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Laura StaffaDepartment of Applied Tumour Biology, Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany, and Clinical Cooperation Unit Applied Tumour Biology, DKFZ (German Cancer Research Center) Heidelberg, Im Neuenheimer Feld 280, Heidelberg, Germany.
Fabian EchterdiekDepartment of Applied Tumour Biology, Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany, and Clinical Cooperation Unit Applied Tumour Biology, DKFZ (German Cancer Research Center) Heidelberg, Im Neuenheimer Feld 280, Heidelberg, Germany.
Nina NeliusDepartment of Applied Tumour Biology, Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany, and Clinical Cooperation Unit Applied Tumour Biology, DKFZ (German Cancer Research Center) Heidelberg, Im Neuenheimer Feld 280, Heidelberg, Germany.
Axel BennerDepartment of Biostatistics, DKFZ (German Cancer Research Center), Im Neuenheimer Feld 280, Heidelberg, Germany.
Wiebke WerftDepartment of Biostatistics, DKFZ (German Cancer Research Center), Im Neuenheimer Feld 280, Heidelberg, Germany.
Bernd LahrmannBioquant, Hamamatsu Tissue Imaging and Analysis (TIGA) Center, Heidelberg, Germany.
Niels GrabeBioquant, Hamamatsu Tissue Imaging and Analysis (TIGA) Center, Heidelberg, Germany.
Martin SchneiderDepartment of General, Visceral and Accident Surgery, University Hospital Heidelberg, Heidelberg Germany.
Mirjam TariverdianDepartment of General, Visceral and Accident Surgery, University Hospital Heidelberg, Heidelberg Germany.
Magnus von Knebel DoeberitzDepartment of Applied Tumour Biology, Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany, and Clinical Cooperation Unit Applied Tumour Biology, DKFZ (German Cancer Research Center) Heidelberg, Im Neuenheimer Feld 280, Heidelberg, Germany.
Hendrik BläkerUniversity Hospital Charité, Department of General Pathology, Berlin, Germany.
Matthias KloorDepartment of Applied Tumour Biology, Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany, and Clinical Cooperation Unit Applied Tumour Biology, DKFZ (German Cancer Research Center) Heidelberg, Im Neuenheimer Feld 280, Heidelberg, Germany.
Heidelberg University · DEUniversity Hospital Heidelberg · DECharité - Universitätsmedizin Berlin · DEGerman Cancer Research Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lynch syndrome is caused by germline mutations of DNA mismatch repair (MMR) genes, most frequently MLH1 and MSH2. Recently, MMR-deficient crypt foci (MMR-DCF) have been identified as a novel lesion which occurs at high frequency in the intestinal mucosa from Lynch syndrome mutation carriers, but very rarely progress to cancer. To shed light on molecular alterations and clinical associations of MMR-DCF, we systematically searched the intestinal mucosa from Lynch syndrome patients for MMR-DCF by immunohistochemistry. The identified lesions were characterised for alterations in microsatellite-bearing genes with proven or suspected role in malignant transformation. We demonstrate that the prevalence of MMR-DCF (mean 0.84 MMR-DCF per 1 cm2 mucosa in the colorectum of Lynch syndrome patients) was significantly associated with patients' age, but not with patients' gender. No MMR-DCF were detectable in the mucosa of patients with sporadic MSI-H colorectal cancer (n = 12). Microsatellite instability of at least one tested marker was detected in 89% of the MMR-DCF examined, indicating an immediate onset of microsatellite instability after MMR gene inactivation. Coding microsatellite mutations were most frequent in the genes HT001 (ASTE1) with 33%, followed by AIM2 (17%) and BAX (10%). Though MMR deficiency alone appears to be insufficient for malignant transformation, it leads to measurable microsatellite instability even in single MMR-deficient crypts. Our data indicate for the first time that the frequency of MMR-DCF increases with patients' age. Similar patterns of coding microsatellite instability in MMR-DCF and MMR-deficient cancers suggest that certain combinations of coding microsatellite mutations, including mutations of the HT001, AIM2 and BAX gene, may contribute to the progression of MMR-deficient lesions into MMR-deficient cancers.

Indexed as

Microsatellite InstabilityAberrant Crypt FociAdaptor Proteins, Signal TransducingAdultAgedAge Factorsbcl-2-Associated X ProteinColorectal Neoplasms, Hereditary NonpolyposisDNA-Binding ProteinsHumansIntestinal MucosaMiddle AgedMutL Protein Homolog 1MutS Homolog 2 ProteinNuclear ProteinsProteinsAdaptor Proteins, Signal TransducingAIM2 protein, humanASTE1 protein, humanBAX protein, humanbcl-2-Associated X ProteinDNA-Binding ProteinsMLH1 protein, humanMSH2 protein, humanMutL Protein Homolog 1MutS Homolog 2 ProteinNuclear ProteinsProteins

Identifiers

PMID25816162
PMCPMC4376900
OpenAlexW2072186927

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.